This month on AJT report, there was a discussion that might be very important.. can generics be trusted?
Some physicians have concerns about the efficacy and safety of many generic immunosuppresive agents for our transplant patients. The small article in AJT nicely points out few important points: we need more data to show to FDA that generic drugs might not be working as well or are working equally well. Name brand drugs go through much more of a validation process. Bio equivalence might vary as high as 40% based on this summary.
Its an important topic that needs further prospective trials in this field.
No comments:
Post a Comment